FDA approves Afrezza for pediatric diabetes patients

Filipino

The U.S. FDA has approved Afrezza for children and adolescents with diabetes ages 6 and older. MannKind Corporation held a conference call on May 29, 2026, to discuss the decision.

MannKind Corporation announced the approval during a call led by CEO Michael Castagna. He described the day as a historic moment for the company, the diabetes community, and young patients. Castagna noted that founder Al Mann had long envisioned the treatment reaching children, and the company is fulfilling that goal.

Mga Kaugnay na Artikulo

Illustration showing long COVID patients revitalized by fluvoxamine treatment in a clinical trial, with scientists and physician highlighting study results.
Larawang ginawa ng AI

Fluvoxamine eases severe fatigue in long COVID patients

Iniulat ng AI Larawang ginawa ng AI

A study shows the antidepressant fluvoxamine reduces severe fatigue in long COVID patients. In a randomized trial of 399 adults, it was compared with metformin and placebo. Physician Judith Bruchfeld describes the findings as interesting.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Iniulat ng AI

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Teknolohiya

Dexcom outlines growth plans at 2026 investor day

Kalusugan

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Kalusugan

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

Iniulat ng AI

A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.

June 14, 2026 20:53

France reimburses Mounjaro and Wegovy for severe obesity

June 10, 2026 04:55

Novo Nordisk heads to South African court over semaglutide copies

May 28, 2026 07:51

Three million kronor for research on mast cells in asthma

May 14, 2026 00:38

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

May 12, 2026 00:48

Semaglutide shows strong weight loss results for adults over 65

May 07, 2026 17:40

Swedish team restores blood sugar control in diabetic mice

May 06, 2026 06:50

Innovative Cape Town clinic boosts outcomes for young kidney patients

April 16, 2026 15:29

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

April 13, 2026 22:13

FDA approves Travere Therapeutics' FILSPARI for FSGS

March 23, 2026 12:25

Study recommends treatment for all children with obesity

Gumagamit ng cookies ang website na ito

Gumagamit kami ng cookies para sa analytics upang mapabuti ang aming site. Basahin ang aming patakaran sa privacy para sa higit pang impormasyon.
Tanggihan